Multifaceted flu vaccine demonstrates wider protection
Scientists at Georgia State University have developed an intranasal influenza vaccine using a new combination of nanoparticles for improved defence against flu strains.
List view / Grid view
News
Researchers identify potential drugs to reduce COVID-19 mortalities
Researchers have established a list of compounds that effect cytokine storms that could reduce mortality in COVID-19 patients.
Model to study oculocutaneous albinism eye conditions developed
The first patient-derived stem cell model to research eye conditions related to oculocutaneous albinism (OCA) has been created.
New model yields promising gene therapy for heart condition
Scientists in Japan have developed a credible heart cell model for arrhythmogenic cardiomyopathy and observed a positive response in the condition using PKP2 gene therapy.
New protein that enables SARS-CoV-2 access into cells identified
Researchers have found that extracellular vimentin facilitates SARS-CoV-2 entry into human cells, presenting a new target.
Sanofi and Exscientia establish strategic research collaboration
Sanofi and Exscientia will develop up to 15 novel drug candidates by leveraging the latter's AI discovery and optimisation platform.
Genes newly linked to ageing and human lifespan
Researchers have found that genes in small organisms, known to extend lifespan, could also impact ageing in humans.
Organoid system simulates human liver-islet axis in diabetes
Scientists have developed a multi-organoid system from stem cells that can replicate the liver-islet axis in type 2 diabetes.
Important Omicron insights to aid treatment success
Knowledge is power – for scientists at least – and thanks to collaborative research from a UK and German university, we now have better understanding of the SARS-CoV-2 Omicron virus, including how it behaves and effective means of treatment.
Gut-brain pathway metabolite involved in age-related cognitive decline, study shows
In mice, researchers have shown that δ-valerobetaine plays a role in neurocognitive ability, making the metabolite a target for age-related memory loss.
Novel DNA-free virus-like particles deliver gene-editing proteins to animal models
Researchers have developed a new drug delivery system using virus-like particles to successfully transport gene-editing proteins in pre-clinical studies.
Avacta selects chemotherapy drug candidate for pre-clinical development
Avacta Group announced that the chemotherapy candidate AVA3996 will be developed with a view to a first-in-human clinical trial beginning in 2023.
Understanding the tau tangles in neurodegeneration could aid treatment discovery
Representing a breakthrough in better understanding how tau proteins cause neurodegenerative disease, scientists have mapped the tau interactome.
Scientists unveil first molecular-level analysis of Omicron spike protein
Using cryo-electron microscopy, researchers have completed the world’s first molecular analysis of the SARS-CoV-2 Omicron spike protein.
Janssen licenses its pan-influenza antibody to Leyden Labs
Janssen's monoclonal antibody CR9114, for the potential treatment of influenza, has been exclusively licensed by Leyden Labs for development and commercialisation.
